MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 326869 | Name: Medroxyprogesterone Acetate
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Medroxyprogesterone Acetate, also known as MPA, is a steroidal progestin, a synthetic variant of the steroid hormone progesterone. It is used as a contraceptive, in hormone replacement therapy and for the treatment of endometriosis as well as several other indications. MPA is a more potent derivative of its parent compound medroxyprogesterone (MP). While medroxyprogesterone is sometimes used as a synonym for medroxyprogesterone acetate, what is almost always being referred to is MPA and not MP It is on the World Health Organization's List of Essential Medicines, the most important medication needed in a basic health system.

Chemical Structure

Medroxyprogesterone Acetate
Medroxyprogesterone Acetate
CAS#71-58-9 (acetate)

Theoretical Analysis

MedKoo Cat#: 326869

Name: Medroxyprogesterone Acetate

CAS#: 71-58-9 (acetate)

Chemical Formula: C24H34O4

Exact Mass: 386.2457

Molecular Weight: 386.53

Elemental Analysis: C, 74.58; H, 8.87; O, 16.56

Price and Availability

Size Price Availability Quantity
250mg USD 250.00 2 weeks
1g USD 550.00 2 weeks
2g USD 850.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
520-85-4 71-58-9 (acetate)
Synonym
Medroxyprogesterone Acetate; MPA; Medroxyprogesterone 17-acetate
IUPAC/Chemical Name
(6S,8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl acetate
InChi Key
PSGAAPLEWMOORI-PEINSRQWSA-N
InChi Code
InChI=1S/C24H34O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h13-14,18-20H,6-12H2,1-5H3/t14-,18+,19-,20-,22+,23-,24-/m0/s1
SMILES Code
CC([C@@]1(OC(C)=O)CC[C@@]2([H])[C@]3([H])C[C@H](C)C4=CC(CC[C@]4(C)[C@@]3([H])CC[C@]12C)=O)=O
Appearance
White to off-white crystalline powder.
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Medroxyprogesterone acetate is a widely used synthetic steroid by its interaction with progesterone, androgen and glucocorticoid receptors.
In vitro activity:
MPA (medroxyprogesterone acetate) significantly impaired wound closure in both cell types and delayed the reestablishment of transepithelial resistance by epithelial cells. In contrast to MPA, NET selectively decreased wound closure by stromal fibroblasts but not epithelial cells. Reference: Sci Rep. 2021 Dec 1;11(1):23246. https://pubmed.ncbi.nlm.nih.gov/34853394/
In vivo activity:
DMPA (Depo-medroxyprogesterone) treatments of both athymic nude mice and heterozygous NU/J (Foxn1nu/+) but ovariectomized mice led to a significantly increased viral load at the anogenital tract, suggesting that endogenous sex hormones were involved in increased viral susceptibility by DMPA treatment. Consistent with previous reports, DMPA treatment suppressed host anti-viral activities at the lower genital tract. Reference: Viruses. 2022 May 6;14(5):980. https://pubmed.ncbi.nlm.nih.gov/35632722/
Solvent mg/mL mM
Solubility
DMSO 11.0 28.46
Water 1.0 2.59
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 386.53 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Patel MV, Rodriguez-Garcia M, Shen Z, Wira CR. Medroxyprogesterone acetate inhibits wound closure of human endometrial epithelial cells and stromal fibroblasts in vitro. Sci Rep. 2021 Dec 1;11(1):23246. doi: 10.1038/s41598-021-02681-6. PMID: 34853394; PMCID: PMC8636475. 2. Vanpouille C, Günaydın G, Jangard M, Clerici M, Margolis L, Broliden K, Introini A. The Progestin Medroxyprogesterone Acetate Affects HIV-1 Production in Human Lymphoid Tissue Explants in a Dose-Dependent and Glucocorticoid-like Fashion. Viruses. 2021 Nov 18;13(11):2303. doi: 10.3390/v13112303. PMID: 34835109; PMCID: PMC8621851. 3. Hu J, Brendle SA, Li JJ, Walter V, Cladel NM, Cooper T, Shearer DA, Balogh KK, Christensen ND. Depo Medroxyprogesterone (DMPA) Promotes Papillomavirus Infections but Does Not Accelerate Disease Progression in the Anogenital Tract of a Mouse Model. Viruses. 2022 May 6;14(5):980. doi: 10.3390/v14050980. PMID: 35632722; PMCID: PMC9147738. 4. Das R, Ragagnin G, Sjöstedt J, Johansson M, Haage D, Druzin M, Johansson S, Bäckström T. Medroxyprogesterone acetate positively modulates specific GABAA-receptor subtypes - affecting memory and cognition. Psychoneuroendocrinology. 2022 Jul;141:105754. doi: 10.1016/j.psyneuen.2022.105754. Epub 2022 Mar 31. PMID: 35395561.
In vitro protocol:
1. Patel MV, Rodriguez-Garcia M, Shen Z, Wira CR. Medroxyprogesterone acetate inhibits wound closure of human endometrial epithelial cells and stromal fibroblasts in vitro. Sci Rep. 2021 Dec 1;11(1):23246. doi: 10.1038/s41598-021-02681-6. PMID: 34853394; PMCID: PMC8636475. 2. Vanpouille C, Günaydın G, Jangard M, Clerici M, Margolis L, Broliden K, Introini A. The Progestin Medroxyprogesterone Acetate Affects HIV-1 Production in Human Lymphoid Tissue Explants in a Dose-Dependent and Glucocorticoid-like Fashion. Viruses. 2021 Nov 18;13(11):2303. doi: 10.3390/v13112303. PMID: 34835109; PMCID: PMC8621851.
In vivo protocol:
1. Hu J, Brendle SA, Li JJ, Walter V, Cladel NM, Cooper T, Shearer DA, Balogh KK, Christensen ND. Depo Medroxyprogesterone (DMPA) Promotes Papillomavirus Infections but Does Not Accelerate Disease Progression in the Anogenital Tract of a Mouse Model. Viruses. 2022 May 6;14(5):980. doi: 10.3390/v14050980. PMID: 35632722; PMCID: PMC9147738. 2. Das R, Ragagnin G, Sjöstedt J, Johansson M, Haage D, Druzin M, Johansson S, Bäckström T. Medroxyprogesterone acetate positively modulates specific GABAA-receptor subtypes - affecting memory and cognition. Psychoneuroendocrinology. 2022 Jul;141:105754. doi: 10.1016/j.psyneuen.2022.105754. Epub 2022 Mar 31. PMID: 35395561.
1: Dragoman MV, Gaffield ME. The safety of subcutaneously administered depot medroxyprogesterone acetate (104mg/0.65mL): A systematic review. Contraception. 2016 Sep;94(3):202-15. doi: 10.1016/j.contraception.2016.02.003. Epub 2016 Feb 10. Review. PubMed PMID: 26874275. 2: Brind J, Condly SJ, Mosher SW, Morse AR, Kimball J. Risk of HIV Infection in Depot-Medroxyprogesterone Acetate (DMPA) Users: A Systematic Review and Meta-analysis. Issues Law Med. 2015 Autumn;30(2):129-39. Review. PubMed PMID: 26710371. 3: Stanczyk FZ, Bhavnani BR. Reprint of "Use of medroxyprogesterone acetate for hormone therapy in postmenopausal women: Is it safe?". J Steroid Biochem Mol Biol. 2015 Sep;153:151-9. doi: 10.1016/j.jsbmb.2015.08.013. Epub 2015 Aug 19. Review. PubMed PMID: 26291834. 4: Ohyagi-Hara C, Sawada K, Aki I, Mabuchi S, Kobayashi E, Ueda Y, Yoshino K, Fujita M, Tsutsui T, Kimura T. Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: our experience and a review of the literature. Arch Gynecol Obstet. 2015 Jan;291(1):151-7. doi: 10.1007/s00404-014-3417-z. Epub 2014 Aug 14. Review. PubMed PMID: 25118836. 5: Stanczyk FZ, Bhavnani BR. Use of medroxyprogesterone acetate for hormone therapy in postmenopausal women: is it safe? J Steroid Biochem Mol Biol. 2014 Jul;142:30-8. doi: 10.1016/j.jsbmb.2013.11.011. Epub 2013 Nov 26. Review. PubMed PMID: 24291402. 6: Curry L, Taylor L, Pallas SW, Cherlin E, Pérez-Escamilla R, Bradley EH. Scaling up depot medroxyprogesterone acetate (DMPA): a systematic literature review illustrating the AIDED model. Reprod Health. 2013 Aug 2;10:39. doi: 10.1186/1742-4755-10-39. Review. PubMed PMID: 23915274; PubMed Central PMCID: PMC3737048. 7: Guirguis-Blake J. Copper intrauterine device vs. depot medroxyprogesterone acetate for contraception. Am Fam Physician. 2011 Jan 1;83(1):35-6. Review. PubMed PMID: 21888124. 8: Gerlach LS, Saldaña SN, Wang Y, Nick TG, Spigarelli MG. Retrospective review of the relationship between weight change and demographic factors following initial depot medroxyprogesterone acetate injection in adolescents. Clin Ther. 2011 Feb;33(2):182-7. doi: 10.1016/j.clinthera.2011.02.008. Epub 2011 Mar 12. Review. PubMed PMID: 21397330. 9: Paulen ME, Curtis KM. When can a woman have repeat progestogen-only injectables--depot medroxyprogesterone acetate or norethisterone enantate? Contraception. 2009 Oct;80(4):391-408. doi: 10.1016/j.contraception.2009.03.023. Epub 2009 Jun 13. Review. PubMed PMID: 19751863. 10: Madeddu C, Macciò A, Panzone F, Tanca FM, Mantovani G. Medroxyprogesterone acetate in the management of cancer cachexia. Expert Opin Pharmacother. 2009 Jun;10(8):1359-66. doi: 10.1517/14656560902960162. Review. PubMed PMID: 19445562. 11: Guilbert ER, Brown JP, Kaunitz AM, Wagner MS, Bérubé J, Charbonneau L, Francoeur D, Gilbert A, Gilbert F, Roy G, Senikas V, Jacob R, Morin R. The use of depot-medroxyprogesterone acetate in contraception and its potential impact on skeletal health. Contraception. 2009 Mar;79(3):167-77. doi: 10.1016/j.contraception.2008.10.016. Epub 2009 Jan 15. Review. PubMed PMID: 19185668. 12: Hermsmeyer RK, Thompson TL, Pohost GM, Kaski JC. Cardiovascular effects of medroxyprogesterone acetate and progesterone: a case of mistaken identity? Nat Clin Pract Cardiovasc Med. 2008 Jul;5(7):387-95. doi: 10.1038/ncpcardio1234. Epub 2008 Jun 3. Review. PubMed PMID: 18521110. 13: Bakry S, Merhi ZO, Scalise TJ, Mahmoud MS, Fadiel A, Naftolin F. Depot-medroxyprogesterone acetate: an update. Arch Gynecol Obstet. 2008 Jul;278(1):1-12. doi: 10.1007/s00404-007-0497-z. Epub 2008 May 10. Review. PubMed PMID: 18470526. 14: Kaunitz AM, Arias R, McClung M. Bone density recovery after depot medroxyprogesterone acetate injectable contraception use. Contraception. 2008 Feb;77(2):67-76. doi: 10.1016/j.contraception.2007.10.005. Review. PubMed PMID: 18226668. 15: Simoncini T, Mannella P, Pluchino N, Genazzani AR. Comparative effects of dydrogesterone and medroxyprogesterone acetate in critical areas: the brain and the vessels. Gynecol Endocrinol. 2007 Oct;23 Suppl 1:9-16. Review. PubMed PMID: 17943534. 16: Shulman LP. A review of drospirenone for safety and tolerability and effects on endometrial safety and lipid parameters contrasted with medroxyprogesterone acetate, levonorgestrel, and micronized progesterone. J Womens Health (Larchmt). 2006 Jun;15(5):584-90. Review. PubMed PMID: 16796485. 17: Black A; Ad Hoc DMPA Committee of the Society of Obstetricians and Gynaecologists of Canada. Canadian contraception consensus--update on Depot Medroxyprogesterone Acetate (dmpa). J Obstet Gynaecol Can. 2006 Apr;28(4):305-13. English, French. PubMed PMID: 16776909. 18: Lo SS, Fan SY; Health Services Subcommittee of the Family Planning Association of Hong Kong. Bone loss associated with long-term use of depot medroxyprogesterone acetate. Hong Kong Med J. 2005 Dec;11(6):491-5. Review. PubMed PMID: 16340026. 19: Ortmann J, Traupe T, Vetter W, Barton M. [Postmenopausal hormone replacement therapy and cardiovascular risk: role of conjugated equine estrogens and medroxyprogesterone acetate]. Praxis (Bern 1994). 2004 May 19;93(21):904-14. Review. German. PubMed PMID: 15216975. 20: Busen NH. Bone mineral density in adolescent women using depot medroxyprogesterone acetate. J Am Acad Nurse Pract. 2004 Feb;16(2):57-62. Review. Erratum in: J Am Acad Nurse Pract. 2004 May;16(5):186. PubMed PMID: 15055422.

View History

Tedizolid phosphate disodium salt

Tedizolid phosphate disodium salt

Iodotyrosine

Iodotyrosine

Tei 6344

Tei 6344